Focal segmental glomerulosclerosis
MONDO:0100313A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.
Also known as: FGS (focal glomerular sclerosis), FSGS, FSGS - focal segmental glomerulosclerosis
56 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a drug stop kidney disease from returning after transplant?
Disease control CompletedThis study tested whether the drug Acthar can prevent focal segmental glomerulosclerosis (FSGS) from coming back in people who receive a kidney transplant. Fifteen adults with FSGS and advanced kidney disease took part. Researchers measured how many had FSGS return by looking at …
Phase: PHASE3 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for FSGS? obinutuzumab trial targets tough cases
Disease control CompletedThis phase 2 trial tested the drug obinutuzumab in 20 adults with a kidney disease called primary FSGS. The participants had not responded well to or could not take standard treatments like steroids. The goal was to see if obinutuzumab could reduce protein leakage in the urine, a…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a common arthritis drug help black patients with kidney disease?
Disease control CompletedThis study tested whether baricitinib, a drug used for arthritis, can safely reduce high protein levels in the urine of African American adults with a specific genetic form of kidney disease (APOL1). Eight participants took the drug to see if it lowered their urine protein and pr…
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New kidney drug shows promise in FSGS trial
Disease control CompletedThis Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise for rare kidney disease in early trial
Disease control CompletedThis study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. Participants took different doses of the medicine or a placebo daily for 12 weeks. The goal was to see if the medicine could reduce protein in the urine, a sign of better kidney health. T…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kidney patients: experimental drug targets protein leak
Disease control CompletedThis study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could r…
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug targets genetic kidney disease in small trial
Disease control CompletedThis study tested a new drug called VX-147 in 16 adults with a specific genetic form of kidney disease (APOL1-mediated FSGS). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, and to check its safety. The drug is taken by mouth and aims t…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Sweat sensor could replace needles for kidney patients
Diagnosis CompletedThis study tested a new wearable patch that collects sweat to measure sodium and creatinine levels, which are important for monitoring kidney health and dehydration. Five adults with kidney disease wore the patch while their sweat was analyzed using a special light-based techniqu…
Phase: NA • Sponsor: Korea University • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Preemptive drug combo may shield new kidneys from FSGS return
Prevention CompletedThis study tested whether giving the drug rituximab along with a blood-filtering procedure called plasmapheresis right before a kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The trial enrolled 21 children and adults with FSGS who were g…
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Prevention
Last updated Jun 26, 2026 16:28 UTC
-
Scientists dig into mysterious kidney scarring
Knowledge-focused CompletedThis completed study looked at why some people develop scarring in their kidneys, including rare diseases like FSGS and a mysterious form of chronic kidney disease affecting farm workers. Researchers collected blood, urine, and kidney tissue from 537 participants to better unders…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Gene hunt for kidney disease FSGS aims to explain racial disparities
Knowledge-focused CompletedThis study searched for genetic factors that may cause focal segmental glomerulosclerosis (FSGS), a kidney disease that can lead to kidney failure. Researchers compared DNA from 616 people, including African-Americans with FSGS, African-Americans with HIV but no FSGS, and non-Afr…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Worldwide kidney study tracks 6,000 patients to unlock disease secrets
Knowledge-focused CompletedThis study followed nearly 6,000 people with kidney disease from around the world. Researchers collected routine test results like kidney function and protein in urine to better understand how the disease progresses. The goal was to gather information, not to test a new treatment…
Sponsor: The George Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC